



FINANCIAL TEAR SHEET

CORPORATE PROFILE

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and a Phase 2 study in refractory indolent Non-Hodgkin's Lymphoma (iNHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018. Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.

PRIMARY IR CONTACT

Brian Sullivan
Corporate Development
Phone: 781-292-4214
Fax: 617-812-0059
E-mail:
bsullivan@verastem.com

STOCK PERFORMANCE

VSTM (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$3.90
Change (%)	▼ 0.25 (6.02%)
Volume	905,781
52 Week Low	\$1.05
Market Cap	\$144,270,430
Rolling EPS	-1.24
PE Ratio	N/A
Shares Outstanding	36,992,418

Data as of 10/18/17 4:00 p.m. ET



RECENT HEADLINES & EVENTS

10/17/17 - 7:00 a.m.

[Verastem Pays Milestone Payment to Infinity Pharmaceuticals](#)

10/11/17 - 4:13 p.m.

[Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer](#)

09/22/17 - 7:15 a.m.

[Verastem to Present at the Cantor Fitzgerald Global Healthcare Conference](#)

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
10/17/17	8-K
10/11/17	4
10/11/17	3
09/25/17	8-K/A

CORPORATE GOVERNANCE

[Robert Forrester, LL.B.](#) President/Chief Executive Officer

[Jonathan Pachter, Ph.D.](#) Chief Scientific Officer

[Dan Paterson](#) Chief Operating Officer

[Hagop Youssoufian, MSc, M.D.](#) Head of Hematology and Oncology Development

[Steven Bloom](#) Vice President, Corporate Development

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed